lumiliximab
Sign in to saveLumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator and was awarded orphan drug status and fast track designation by the FDA.
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Lumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator and was awarded orphan drug status and fast track designation by the FDA.
It was investigated in Phase II/III clinical trials for the treatment of chronic lymphocytic leukemia. It has also been studied for use in allergic asthma. The drug is a chimeric antibody from Macaca irus and Homo sapiens.
Excerpted from Wikipedia’s “lumiliximab” article, available under the CC BY-SA 4.0 licence.